Centrus Energy Corp. heads into its May 5 earnings release carrying one of the most crowded short positions in the market — and a track record of sharp post-earnings moves that will test both sides of the trade.
Short sellers have a firm grip on the stock. Short interest is running at 24.1% of free float, with nearly 4.2 million shares borrowed. The ORTEX short score is 72.8 — in the bottom 3rd percentile of the entire universe — and days to cover has stretched to over nine days, meaning any rush to cover would take significant time to unwind. Availability is exceptionally tight: the lending pool has been close to fully drained for most of April, with utilization hitting 100% on multiple sessions. Cost to borrow has climbed sharply, rising 28% over the past week to 1.09% — still not punishingly expensive in absolute terms, but the direction is notable ahead of the print.
Options positioning is only modestly more defensive than usual. The put/call ratio is 0.72, just above its 20-day average of 0.70 and roughly 1.2 standard deviations elevated — far from alarming. The wider market is not piling on additional downside protection here, even with short interest this high. The stock itself has recovered well, up 19% over the past month to $206.64, though it slipped 2% on Friday. Peers across the uranium and nuclear fuel space — LTBR, , — all surged 6–15% on Friday while LEU gave back ground, a divergence worth watching.
The bull and bear cases are well-defined and fundamentally opposed. Bulls point to Centrus's $1.6 billion cash position, its DOE HALEU operations contract delivering 31% Technical Solutions revenue growth, and a stock that has massively outperformed peers on a trailing-twelve-month basis. Bears focus on a cluster of structural threats: import waiver risk, the looming 2028 loss of Russian LEU supply, and execution risk on first-of-a-kind commercial deployment of the AC100 enrichment centrifuge. B. Riley — one of the few Buy-rated firms — trimmed its target from $315 to $295 on April 24, citing caution while maintaining conviction. JPMorgan and Citi have held Neutral ratings with targets in the $225–$242 range, all above the current price but well below the $357 Needham target — illustrating how wide the analyst dispersion has become.
The most sobering context is recent earnings history. The last confirmed print in February triggered a one-day drop of over 30% and a five-day decline of roughly 22%. The May 5 report will test whether the 19% rebound since then reflects genuine re-rating or simply the passage of time — and whether the heavily loaded short base provides a floor or fuel for the next leg down.
See the live data behind this article on ORTEX.
Open LEU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
